{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:14:15Z","timestamp":1791828855202,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004825","name":"Nordea-fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004825","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss Federal Institute of Technology Zurich"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40264-024-01490-w","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T14:10:25Z","timestamp":1732716625000},"page":"191-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase"],"prefix":"10.1007","volume":"48","author":[{"given":"Adrian","family":"Martinez de la Torre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Bech","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Burden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1087-7597","authenticated-orcid":false,"given":"Stefan","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"1","key":"1490_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78. https:\/\/doi.org\/10.1038\/nrd.2017.267.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"1490_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102390","volume":"18","author":"Y Jamilloux","year":"2019","unstructured":"Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, S\u00e8ve P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11): 102390. https:\/\/doi.org\/10.1016\/j.autrev.2019.102390.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1490_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133\u201345. https:\/\/doi.org\/10.1038\/s41584-021-00726-8.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1490_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.23177","volume":"58","author":"CG Helmick","year":"2008","unstructured":"Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15\u201325. https:\/\/doi.org\/10.1002\/art.23177.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1490_CR5","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/jcm10061241","volume":"10","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y. Managing osteoporosis and joint damage in patients with rheumatoid arthritis: an overview. J Clin Med. 2021;10(6):1241.","journal-title":"J Clin Med"},{"issue":"3","key":"1490_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00198-012-2240-2","volume":"24","author":"F Borgstr\u00f6m","year":"2013","unstructured":"Borgstr\u00f6m F, Lekander I, Iverg\u00e5rd M, Str\u00f6m O, Svedbom A, Alekna V, et al. The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)\u2013quality of life during the first 4 months after fracture. Osteoporos Int. 2013;24(3):811\u201323. https:\/\/doi.org\/10.1007\/s00198-012-2240-2.","journal-title":"Osteoporos Int"},{"issue":"6","key":"1490_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/art.1780360603","volume":"36","author":"DJ Cook","year":"1993","unstructured":"Cook DJ, Guyatt GH, Adachi JD, Clifton J, Griffith LE, Epstein RS, et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum. 1993;36(6):750\u20136. https:\/\/doi.org\/10.1002\/art.1780360603.","journal-title":"Arthritis Rheum"},{"issue":"Supplement_6","key":"1490_CR8","doi-asserted-by":"publisher","first-page":"vi12","DOI":"10.1093\/rheumatology\/keab609","volume":"60","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology. 2021;60(Supplement_6):vi12\u201320. https:\/\/doi.org\/10.1093\/rheumatology\/keab609.","journal-title":"Rheumatology"},{"issue":"6","key":"1490_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000493390","volume":"27","author":"J Bullock","year":"2018","unstructured":"Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, et al. Rheumatoid arthritis: a brief overview of the treatment. Med Princ Pract. 2018;27(6):501\u20137. https:\/\/doi.org\/10.1159\/000493390.","journal-title":"Med Princ Pract"},{"issue":"2","key":"1490_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s00223-006-0020-8","volume":"79","author":"P Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int. 2006;79(2):84\u201394. https:\/\/doi.org\/10.1007\/s00223-006-0020-8.","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"1490_CR11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/annrheumdis-2019-215328","volume":"78","author":"G Ozen","year":"2019","unstructured":"Ozen G, Pedro S, Wolfe F, Michaud K. Medications associated with fracture risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(8):1041\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215328.","journal-title":"Ann Rheum Dis"},{"key":"1490_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.680043","volume":"12","author":"S Shams","year":"2021","unstructured":"Shams S, Martinez JM, Dawson JRD, Flores J, Gabriel M, Garcia G, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol. 2021;12: 680043. https:\/\/doi.org\/10.3389\/fphar.2021.680043.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1490_CR13","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez J-B. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023\u201338. https:\/\/doi.org\/10.1021\/jm401490p.","journal-title":"J Med Chem"},{"key":"1490_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001","author":"AM Shawky","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14051001.","journal-title":"Pharmaceutics"},{"key":"1490_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay4447","author":"S Adam","year":"2020","unstructured":"Adam S, Simon N, Steffen U, Andes FT, Scholtysek C, M\u00fcller DIH, et al. JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aay4447.","journal-title":"Sci Transl Med."},{"key":"1490_CR16","unstructured":"European Medicines Agency. Xeljanz; procedural steps taken and scientific information after the authorisation. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz. Accessed 19 Apr 2024."},{"key":"1490_CR17","unstructured":"European Medicines Agency. Xeljanx (tofacitinib). 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz. Accessed 19 Apr 2024."},{"issue":"8","key":"1490_CR18","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00198-021-05871-0","volume":"32","author":"A Hamar","year":"2021","unstructured":"Hamar A, Szekanecz Z, Pusztai A, Cz\u00f3kolyov\u00e1 M, V\u00e9gh E, Peth\u0151 Z, et al. Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporos Int. 2021;32(8):1621\u20139. https:\/\/doi.org\/10.1007\/s00198-021-05871-0.","journal-title":"Osteoporos Int"},{"key":"1490_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x221142346","author":"KE Hansen","year":"2022","unstructured":"Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, et al. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022. https:\/\/doi.org\/10.1177\/1759720x221142346.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"1","key":"1490_CR20","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","volume":"12","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12(1):7140. https:\/\/doi.org\/10.1038\/s41598-022-10777-w.","journal-title":"Sci Rep"},{"key":"1490_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.792877","author":"Y-K Song","year":"2022","unstructured":"Song Y-K, Song J, Kim K, Kwon J-W. Potential adverse events reported with the Janus kinase inhibitors approved for the treatment of rheumatoid arthritis using spontaneous reports and online patient reviews. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2021.792877.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1490_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"key":"1490_CR23","unstructured":"Uppsala Monitoring Centre. Guideline for using VigiBase data in studies (version 4). 2021. https:\/\/who-umc.org\/media\/05kldqpj\/guidelineusingvigibaseinstudies.pdf. Accessed 19 Apr 2024."},{"issue":"5","key":"1490_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409\u201319. https:\/\/doi.org\/10.1177\/009286150804200501.","journal-title":"Drug Inf J"},{"issue":"6","key":"1490_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336. https:\/\/doi.org\/10.1002\/pds.1742.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1490_CR26","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module IX Addendum I\u2014methodological aspects of signal detection from spontaneous reports of suspected adverse reactions. 2017. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/good-pharmacovigilance-practices. Accessed 18 Apr 2024."},{"issue":"6","key":"1490_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585\u201399. https:\/\/doi.org\/10.1007\/s40264-024-01423-7.","journal-title":"Drug Saf"},{"issue":"7","key":"1490_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181126","volume":"12","author":"K Murakami","year":"2017","unstructured":"Murakami K, Kobayashi Y, Uehara S, Suzuki T, Koide M, Yamashita T, et al. A Jak1\/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS ONE. 2017;12(7): e0181126. https:\/\/doi.org\/10.1371\/journal.pone.0181126.","journal-title":"PLoS ONE"},{"issue":"1","key":"1490_CR29","doi-asserted-by":"publisher","DOI":"10.2196\/33311","volume":"8","author":"S Park","year":"2022","unstructured":"Park S, Choi SH, Song YK, Kwon JW. Comparison of online patient reviews and national pharmacovigilance data for tramadol-related adverse events: comparative observational study. JMIR Public Health Surveill. 2022;8(1): e33311. https:\/\/doi.org\/10.2196\/33311.","journal-title":"JMIR Public Health Surveill"},{"issue":"7","key":"1490_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865\u201375. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219012.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1490_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41232-023-00268-4","volume":"43","author":"S Yari","year":"2023","unstructured":"Yari S, Kikuta J, Shigyo H, Miyamoto Y, Okuzaki D, Furusawa Y, et al. JAK inhibition ameliorates bone destruction by simultaneously targeting mature osteoclasts and their precursors. Inflamm Regen. 2023;43(1):18. https:\/\/doi.org\/10.1186\/s41232-023-00268-4.","journal-title":"Inflamm Regen."},{"issue":"11","key":"1490_CR32","doi-asserted-by":"publisher","first-page":"9087","DOI":"10.1007\/s11033-020-05910-9","volume":"47","author":"ER Sanpaolo","year":"2020","unstructured":"Sanpaolo ER, Rotondo C, Cici D, Corrado A, Cantatore FP. JAK\/STAT pathway and molecular mechanism in bone remodeling. Mol Biol Rep. 2020;47(11):9087\u201396. https:\/\/doi.org\/10.1007\/s11033-020-05910-9.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"1490_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4049\/jimmunol.171.1.142","volume":"171","author":"SM Khapli","year":"2003","unstructured":"Khapli SM, Mangashetti LS, Yogesha SD, Wani MR. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. J Immunol. 2003;171(1):142\u201351. https:\/\/doi.org\/10.4049\/jimmunol.171.1.142.","journal-title":"J Immunol"},{"issue":"19","key":"1490_CR34","doi-asserted-by":"publisher","first-page":"7850","DOI":"10.1074\/jbc.RA119.008074","volume":"294","author":"NE McGregor","year":"2019","unstructured":"McGregor NE, Murat M, Elango J, Poulton IJ, Walker EC, Crimeen-Irwin B, et al. IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis. J Biol Chem. 2019;294(19):7850\u201363. https:\/\/doi.org\/10.1074\/jbc.RA119.008074.","journal-title":"J Biol Chem"},{"issue":"1","key":"1490_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13075-017-1249-5","volume":"19","author":"SP Raychaudhuri","year":"2017","unstructured":"Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther. 2017;19(1):51. https:\/\/doi.org\/10.1186\/s13075-017-1249-5.","journal-title":"Arthritis Res Ther"},{"key":"1490_CR36","unstructured":"Uppsala Monitoring Centre. Caveat Document. Statement of reservations, limitations and conditions relating to data released from VigiBase, the WHO global database of reported potential side effects of medicinal products. 2021. https:\/\/who-umc.org\/media\/yzpnzmdv\/umc_caveat.pdf. Accessed 19 Apr 2024."},{"issue":"1","key":"1490_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1490_CR38","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339. https:\/\/doi.org\/10.1002\/acr.24596.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1490_CR39","unstructured":"European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 2022. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic. Accessed 19 Apr 2024."},{"key":"1490_CR40","unstructured":"European Medicines Agency. Rinvoq (upadacitinib). 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq. Accessed 19 Apr 2024."},{"issue":"9","key":"1490_CR41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40264-020-00958-9","volume":"43","author":"E Vallejo-Yag\u00fce","year":"2020","unstructured":"Vallejo-Yag\u00fce E, Weiler S, Micheroli R, Burden AM. Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO VigiBase. Drug Saf. 2020;43(9):881\u201391. https:\/\/doi.org\/10.1007\/s40264-020-00958-9.","journal-title":"Drug Saf"},{"issue":"10","key":"1490_CR42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891\u20138. https:\/\/doi.org\/10.2165\/00002018-200730100-00007.","journal-title":"Drug Saf"},{"issue":"3","key":"1490_CR43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/iwj.12231","volume":"12","author":"A Bigham-Sadegh","year":"2015","unstructured":"Bigham-Sadegh A, Oryan A. Basic concepts regarding fracture healing and the current options and future directions in managing bone fractures. Int Wound J. 2015;12(3):238\u201347. https:\/\/doi.org\/10.1111\/iwj.12231.","journal-title":"Int Wound J"},{"issue":"3","key":"1490_CR44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1055\/s-0041-1732334","volume":"35","author":"H ElHawary","year":"2021","unstructured":"ElHawary H, Baradaran A, Abi-Rafeh J, Vorstenbosch J, Xu L, Efanov JI. Bone Healing and inflammation: principles of fracture and repair. Semin Plast Surg. 2021;35(3):198\u2013203. https:\/\/doi.org\/10.1055\/s-0041-1732334.","journal-title":"Semin Plast Surg"},{"issue":"6","key":"1490_CR45","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00198-018-4473-1","volume":"29","author":"S Jin","year":"2018","unstructured":"Jin S, Hsieh E, Peng L, Yu C, Wang Y, Wu C, et al. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int. 2018;29(6):1263\u201375. https:\/\/doi.org\/10.1007\/s00198-018-4473-1.","journal-title":"Osteoporos Int"},{"issue":"36","key":"1490_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000006983","volume":"96","author":"AL Xue","year":"2017","unstructured":"Xue AL, Wu SY, Jiang L, Feng AM, Guo HF, Zhao P. Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore). 2017;96(36): e6983. https:\/\/doi.org\/10.1097\/md.0000000000006983.","journal-title":"Medicine (Baltimore)"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01490-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01490-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01490-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T09:06:28Z","timestamp":1738314388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01490-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01490-w","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"17 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Swiss Federal Institute of Technology Zurich.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Andreas Clausen received travel funding during the project from Novo Nordisk and Nordea. Stefan Weiler is a member of the Human Medicine Expert Committee of Swissmedic. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the competent authority or one of its committees or working parties. While the authors used data from VigiBase, the World Health Organization (WHO) global database of individual case report forms, as a source of information, the conclusions do not represent the opinion of the Uppsala Monitoring Centre (UMC) or the World Health Organization. The remaining authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki. VigiBase\u00ae, the WHO global database of individual case safety reports (ICSRs), is the source of the information; the information comes from a variety of sources, and the probability that the suspected adverse effect is drug related is not the same in all cases; the information does not represent the opinion of the Uppsala Monitoring Centre (UMC) or the World Health Organization (WHO). According to WHO policy and UMC guidelines, reports sent from the WHO Programme for International Drug Monitoring member countries to VigiBase\u00ae are anonymized. Identifiable data are not available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patient consent was waived as VigiBase\n                      \u00ae\n                      database contains anonymized data that cannot allow patients\u2019 identification.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors do not have the authority to share the study data. Access to VigiBase and VigiLyze is handled directly by the Uppsala Monitoring Centre (\n                      \n                      ).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The code will be made available upon reasonable request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Andreas Clausen: Methodology; Formal analysis; Investigation; Interpretation of results; Writing original draft; Literature review and implementation of the study. Stefan Weiler: Conceptualization; Supervision; Interpretation of results. Adrian Martinez-De la Torre: Formal analysis, Interpretation of results, Writing original revision; Methodology; Contributed to the design and implementation of the study; Interpretation of results. Andrea Burden: Methodology; Contributed to the design and implementation of the study; Interpretation of results. All authors reviewed and contributed critically to the manuscript. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}